Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04623801 · ClinicalTrials.gov registry record · Phase 2
Laser Ablation of Papillary Thyroid Microcarcinoma
A Phase 2 study of Thyroid Cancer and Thyroid, sponsored by Memorial Sloan Kettering Cancer Center.
- Active
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04623801: Active Phase 2 study of Thyroid Cancer and Thyroid, sponsored by Memorial Sloan Kettering Cancer Center.
NCT04623801 is a Phase 2 study of Thyroid Cancer and Thyroid that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 10 participants, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04623801, a Phase 2 study of Thyroid Cancer and Thyroid, is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
The purpose of this study is to explore whether percutaneous laser ablation (PLA) is a safe and effective alternative to removing papillary thyroid microcarcinoma (PTMC) with surgery.
Primary Outcome
Complete thermal ablation of the targeted PTMC (T1aN0M0) as determined by histological examination of thyroid tissue obtained by either thyroid lobectomy or total thyroidectomy 6 months after PLA.
Conditions Studied
Interventions
- PROCEDURE Percutaneous Laser Ablation (PLA)
Study Locations (1)
New York
- Memorial Sloan Kettering Cancer Center - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2020-10-19 |
| Est. Completion | 2026-10 |
| Phase | Phase 2 |
What the registry record for NCT04623801 still lists
NCT04623801 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 10 participants, a relatively small participant target, below the 282-participant average among 46 other Thyroid Cancer trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with Thyroid Cancer appearing as the primary indexed condition, and to 1 intervention - of which Percutaneous Laser Ablation (PLA) is the first listed.
NCT04623801 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT04623801 about?
NCT04623801 is a clinical study titled "Laser Ablation of Papillary Thyroid Microcarcinoma". The purpose of this study is to explore whether percutaneous laser ablation (PLA) is a safe and effective alternative to removing papillary thyroid microcarcinoma (PTMC) with surgery.
What is the current status of trial NCT04623801?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2020-10-19. Estimated completion is 2026-10.
What conditions does trial NCT04623801 study?
This clinical trial studies the following conditions: Thyroid Cancer, Thyroid, Papillary Thyroid Microcarcinoma.
What interventions are being tested in trial NCT04623801?
The interventions under investigation include: Percutaneous Laser Ablation (PLA) (PROCEDURE).
Who is sponsoring clinical trial NCT04623801?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04623801 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Thyroid Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04623801's enrollment target sits among peer trials
10 44th of 46 higher than 2 of 46 other Thyroid Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Thyroid Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Zanzalintinib for the Treatment of Advanced Thyroid Cancer Before Surgery
RECRUITING · Phase 2
-
The Use of 124-I-PET/CT Whole Body and Lesional Dosimetry in Differentiated Thyroid Cancer
RECRUITING · Phase 2
-
Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC
RECRUITING · Phase 2
-
A Study of Avutometinib and Defactinib in People With Thyroid Cancer
RECRUITING · Phase 2
-
Comparison of I-124 PET/CT for the Diagnosis of Thyroid Cancer
RECRUITING · Phase 2
-
Lenvatinib 24 mg/Day Versus 10 mg/Day to Treat Symptomatic or Progressive Radioactive Iodine Resistant (RAIR) Differentiated Thyroid Cancer (DTC)
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00623389 · 10 participants · NA
Evaluation of an Advanced Lower Extremity Neuroprostheses
- NCT01241864 · 10 participants · Phase 2
Islet Transplantation in Type 1 Diabetic Kidney Allograft
- NCT01293214 · 10 participants · NA
Vascularized Composite Allotransplantation for Multiple Extremity Amputations
- NCT01474148 · 10 participants · NA
A Neuroprosthesis for Seated Posture and Balance
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI